Imaging Biomarker Dynamics in an Intracranial Murine Glioma Study of Radiation and Antiangiogenic Therapy

Chung, Caroline; Jalali, Shahrzad; Foltz, Warren D.; Burrell, Kelly; Wildgoose, Petra; Lindsay, Patricia; Graves, Christian; Camphausen, Kevin; Milosevic, Michael; Jaffray, David A.; Zadeh, Gelareh; Ménard, Cynthia

doi:10.1016/j.ijrobp.2012.07.005

Cited by 31 publications

(24 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serial multiparametric MRI protocol was carried out on a 7-Tesla Bruker MRI system to look at anatomy and perfusion, as previously described (18).…”

Section: Mrimentioning

confidence: 99%

VEGF Regulates Region-Specific Localization of Perivascular Bone Marrow–Derived Cells in Glioblastoma

et al. 2014

Self Cite

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is characterized by a pathogenic vasculature that drives aggressive local invasion. Recent work suggests that GBM cells recruit bone marrow-derived progenitor cells (BMDC) to facilitate recurrence after radiotherapy, but how this may be achieved is unclear. In this study, we established the spatiotemporal and regional contributions of perivascular BMDCs (pBMDC) to GBM development. We found an increased recruitment of BMDCs to GBM in response to tumor growth and following radiotherapy. However, in this study, BMDCs did not differentiate into endothelial cells directly but rather provided a perivascular support role. The pBMDCs were shown to associate with tumor vasculature in a highly region-dependent manner, with central vasculature requiring minimal pBMDC support.

show abstract

“…Serial multiparametric MRI protocol was carried out on a 7-Tesla Bruker MRI system to look at anatomy and perfusion, as previously described (18).…”

Section: Mrimentioning

confidence: 99%

VEGF Regulates Region-Specific Localization of Perivascular Bone Marrow–Derived Cells in Glioblastoma

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Magnetic resonance imaging (MRI) plays a major role in the current management of brain tumors, including diagnosis and response assessment following treatment [8]. Several tumor parameters extracted from diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE)-MRI have received attention as useful noninvasive biomarkers that can reflect cellular and vascular tumor responses to local or systemic treatment.…”

Section: Introductionmentioning

confidence: 99%

Multiparametric MR imaging of tumor response to intraarterial chemotherapy in orthotopic xenograft models of human metastatic brain tumor

Kim

et al. 2016

J Neurooncol

View full text Add to dashboard Cite

The purpose of our study was to investigate the therapeutic efficacy of intraarterial (IA) chemotherapy via multiparametric magnetic resonance imaging (MRI) analysis in orthotopic mouse brain tumor models. Stereotactic-guided intracranial inoculation of MDA-MB-231 cells was performed in nude mice. Thirty tumor bearing mice were randomized into three groups, and each group received either IA docetaxel administration (n = 10), intravenous (IV) docetaxel administration (n = 10), or IA solvent injection (n = 10) as control. Treatment response was monitored by diffusion-weighted imaging and dynamic contrast enhanced-MRI obtained 1 day before and 8 days after therapy initiation. Imaging results were correlated with histopathology. In the results, IA chemotherapy showed a significant decrease in tumor volume (86.5 ± 15.6 %) compared to the IV chemotherapy (121.1 ± 39.6%) and control (126.2 ± 22.0%) 8 days after therapy (p < 0.05). Furthermore, IA chemotherapy resulted in a significant increase in mean tumor apparent diffusion coefficient (ADC) values (116.8 ± 44.9%); in contrary IV chemotherapy (66.6 ± 26.9%) and control (69.1 ± 29.5%) showed a significant decrease in ADC values corresponding to further tumor growth (p < 0.05). However, there was no significant difference in perfusion parameters including initial area under the curve, K(trans), K(ep), and V(e) between the groups (p > 0.05). Histopathology confirmed necrosis and necroptosis in the tumors after IA chemotherapy. In conclusion, IA chemotherapy may lead to effective inhibition of tumor cell proliferation and offer potential benefit of inducing higher degree of treatment response than IV chemotherapy.

show abstract

“…A similar mouse glioma model has also shown changes in MR perfusion and diffusion after radiation treatments. [12] This same model has demonstrated similar MR perfusion and diffusion changes after combination chemo- and radiation therapy. [12] Diffusion tensor MRI has been reported to be helpful in distinguishing radiation necrosis and viable glioma in a rat radiation necrosis model.…”

Section: Animal Models Of Radiation Necrosismentioning

confidence: 92%

Treatment-related brain tumor imaging changes: So-called "Pseudoprogression" vs. tumor progression: Review and future research opportunities

Tran

Jensen²

2013

Surg Neurol Int

View full text Add to dashboard Cite

Background:Glioblastoma multiforme (GBM) has a dismal prognosis despite aggressive therapy. Initial diagnosis and measurement of response to treatment is usually determined by measurement of gadolinium-enhanced tumor volume with magnetic resonance imaging (MRI). Unfortunately, many GBM treatment modalities can cause changes in tumor gadolinium enhancement patterns that mimic tumor progression. The lack of a definitive imaging modality to distinguish posttreatment radiographic imaging changes (PTRIC), including pseudoprogression and radiation necrosis, from true tumor progression presents a major unmet clinical need in the management of GBM patients.Methods:The authors discuss current modalities available for differentiating PTRIC and tumor progression, describe development of an animal model of PTRIC, and consider potential molecular and cellular pathways involved in the development of PTRIC.Results:An animal model using glioma cells transfected with a luciferase reporter has been developed, and after conventional GBM therapy, this animal model can be evaluated with posttreatment bioluminescence imaging and various MR tumor imaging modalities.Conclusions:Posttreatment radiographic changes that mimic tumor progression can influence clinicians to make treatment decisions that are inappropriate for the patient's actual clinical condition. Several imaging modalities have been used to try to distinguish PTRIC and true progression, including conventional MRI, perfusion MRI, MR spectroscopy, and positron emission tomography (PET); however, none of these modalities has consistently and reliably distinguished PTRIC from tumor growth. An animal model using glioma cells transfected with a luciferase reporter may enable mechanistic studies to determine causes and potential treatments for PTRIC.

show abstract

Imaging Biomarker Dynamics in an Intracranial Murine Glioma Study of Radiation and Antiangiogenic Therapy

Abstract: Early quantitative changes in diffusion and perfusion MRI measures reflect treatment responses soon after starting therapy and thereby raise the potential for these imaging biomarkers to guide adaptive and potentially individualized therapy approaches in the future.

Cited by 31 publications

References 14 publications

VEGF Regulates Region-Specific Localization of Perivascular Bone Marrow–Derived Cells in Glioblastoma

VEGF Regulates Region-Specific Localization of Perivascular Bone Marrow–Derived Cells in Glioblastoma

Multiparametric MR imaging of tumor response to intraarterial chemotherapy in orthotopic xenograft models of human metastatic brain tumor

Treatment-related brain tumor imaging changes: So-called "Pseudoprogression" vs. tumor progression: Review and future research opportunities

Contact Info

Product

Resources

About